8-K: XOMA Corp Earns $9 Million Milestone Following FDA Approval of Day One's OJEMDA

XOMA Corporation has secured a $9 million milestone payment due to the FDA's approval of Day One Biopharmaceuticals' OJEMDA for pediatric low-grade glioma treatment.

Summary

• XOMA Corporation has received a $9 million milestone payment following the FDA's approval of Day One Biopharmaceuticals' drug, OJEMDA.
• OJEMDA is approved for treating patients 6 months and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring specific BRAF alterations.
• XOMA is also entitled to a mid-single digit royalty on global sales of OJEMDA.
• In March 2021, XOMA invested $13.5 million to acquire potential milestones and royalties associated with tovorafenib, the active ingredient in OJEMDA.
• The total potential milestones associated with tovorafenib were $54 million.
• XOMA operates as a biotechnology royalty aggregator, acquiring future economics from therapeutic candidates.

Sentiment

Score: 8

Explanation: The document is positive due to the milestone payment and FDA approval, indicating a successful investment for XOMA. The future outlook is also positive, although it is subject to risks.

Positives

• The $9 million milestone payment provides immediate revenue for XOMA.
• The FDA approval of OJEMDA validates XOMA's investment strategy in acquiring royalty rights.
• The mid-single digit royalty on global sales of OJEMDA provides a potential long-term revenue stream.
• The approval of OJEMDA is a significant advancement in treatment options for children with pLGG.

Risks

• The success of OJEMDA is dependent on its commercial performance, which is subject to market conditions and competition.
• XOMA's future revenue is dependent on the success of its partners' drug development and commercialization efforts.
• There is no guarantee that other investigational compounds in XOMA's portfolio will receive regulatory approval or achieve commercial success.
• The biotechnology industry is subject to inherent risks, including regulatory hurdles and the need for substantial funding for development.

Future Outlook

XOMA anticipates potential future commercial payments from OJEMDA and other partnered programs, with the potential for substantial milestone and royalty proceeds over time. However, these are forward-looking statements and are subject to risks and uncertainties.

Management Comments

• Owen Hughes, Chief Executive Officer of XOMA, stated that the FDA approval is an important milestone for XOMA's royalty portfolio and a watershed event for children with low-grade gliomas.

Industry Context

This announcement highlights the growing trend of royalty aggregation in the biotechnology sector, where companies like XOMA acquire rights to future revenue streams from drug development. The approval of OJEMDA also underscores the ongoing efforts to develop targeted therapies for rare pediatric cancers.

Comparison to Industry Standards

• XOMA's business model is similar to other royalty aggregators like Royalty Pharma, which also acquires royalty streams from pharmaceutical products.
• The $9 million milestone payment is a significant event for XOMA, but the long-term value will depend on the commercial success of OJEMDA, which is comparable to other drugs in the oncology space.
• The mid-single digit royalty rate is within the typical range for pharmaceutical royalties, but the actual revenue will depend on the sales volume of OJEMDA.
• The initial investment of $13.5 million for potential milestones of $54 million is a typical risk/reward profile for this type of investment.

Stakeholder Impact

• Shareholders will benefit from the milestone payment and potential future royalties.
• Patients with pLGG will benefit from the availability of a new treatment option.
• Day One Biopharmaceuticals will benefit from the FDA approval and commercialization of OJEMDA.

Next Steps

• XOMA will continue to monitor the commercial performance of OJEMDA.
• XOMA will continue to pursue opportunities to acquire additional royalty and milestone rights.

Key Dates

Keywords

XOMA, OJEMDA, tovorafenib, FDA approval, milestone payment, royalty, pediatric low-grade glioma, BRAF, biotechnology, royalty aggregator